Efficacy of Telitacicept in treating IgA vasculitis nephritis: a two-case report

Front Immunol. 2025 May 1:16:1564242. doi: 10.3389/fimmu.2025.1564242. eCollection 2025.

Abstract

Telitacicept, a B lymphocyte stimulator/A proliferation-inducing ligand dual-target fusion protein, mainly used for IgA nephropathy and systemic lupus erythematosus. We present two cases where adult patients with IgA vasculitis (IgAV) nephritis were successfully treated with Telitacicept, experienced no adverse reactions during the follow-up. Therefore, Telitacicept represents a promising additional treatment option for patients suffering from IgA vasculitis (IgAV).

Keywords: APRIL; BAFF; Henoch-Schönlein purpura (HSP); IgA vasculitis; Telitacicept.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Glomerulonephritis, IGA* / diagnosis
  • Glomerulonephritis, IGA* / drug therapy
  • Glomerulonephritis, IGA* / immunology
  • Humans
  • IgA Vasculitis* / diagnosis
  • IgA Vasculitis* / drug therapy
  • IgA Vasculitis* / immunology
  • Immunoglobulin A* / immunology
  • Recombinant Fusion Proteins* / administration & dosage
  • Recombinant Fusion Proteins* / adverse effects
  • Treatment Outcome

Substances

  • Immunoglobulin A
  • Recombinant Fusion Proteins
  • telitacicept